SHL TelemedicineSHMLF 52 Debt-to-EBITDA is -1.08 as of Dec. 2025. GuruFocus rates SHMLF with a GF Score™ of 52/100 and a GF Value™ of $12.09. The stock has 3 warning signs investors should review. Among 477 Healthcare Providers & Services companies, SHL Telemedicine ranks worse than 209643.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for SHL Telemedicine's Debt-to-EBITDA or its related term are showing as below:
SHMLF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.3 Med: 1.52 Max: 20.53
Current: -2.17
During the past 13 years, the highest Debt-to-EBITDA Ratio of SHL Telemedicine was 20.53. The lowest was -4.30. And the median was 1.52.
SHMLF's Debt-to-EBITDA is ranked worse than 100% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs SHMLF: -2.17
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHL Telemedicine Debt-to-EBITDA Related Terms
SHL Telemedicine Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for SHL Telemedicine's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHMLF vs VEEV, BTSG, TEM: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, SHL Telemedicine's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
SHL Telemedicine (SHMLF) has a Debt-to-EBITDA of -1.08 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SHL Telemedicine. According to the industry distribution chart, SHL Telemedicine ranks #999999 out of 477 companies in the Healthcare Providers & Services industry.
Is SHL Telemedicine's Debt-to-EBITDA too high?
SHL Telemedicine's current Debt-to-EBITDA is -1.08. Based on the distribution chart, SHL Telemedicine ranks #999999 out of 477 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, SHL Telemedicine has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #999999 out of 477 companies for Debt-to-EBITDA. This places SHL Telemedicine in the lower half of its industry. The industry median Debt-to-EBITDA is 2.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SHL Telemedicine. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current Debt-to-EBITDA is -1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current Debt-to-EBITDA of -1.08. The stock's GF Value™ is $12.09, compared to a current price of $4.84 — trading 59.9% below its estimated fair value. The current Debt-to-EBITDA is -1.08. SHL Telemedicine's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current Debt-to-EBITDA is -1.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (SHMLF) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of $4.84 is trading 59.9% below its estimated GF Value™ of $12.09.
Key valuation signals for SHMLF:
Debt-to-EBITDA: -1.08
GF Value™: $12.09 vs. price of $4.84 (59.9% below fair value)
No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
52GF Score
Get the complete analysis for SHMLF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHMLF has been successfully added to your 
